HSP90 inhibition offers a multi-pronged attack on many aberrant pathways critical for prostate tumor maintenance and intrinsic radioresistance given the diverse clientele of HSP90 [103,104]. This evidence concerns the gene HSP90AB1 and prostate neoplasm.